{"filing":{"accession_number":"0001213900-26-062802","cik":"0001870404","ticker":"CEROW","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","form":"8-K","filing_date":"2026-05-29","report_date":null,"primary_document":"ea0292715-8k_cero.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026062802/ea0292715-8k_cero.htm"},"events":[{"id":8150,"run_id":7155,"accession_number":"0001213900-26-062802","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"The Company issued a $750,000 convertible promissory note with a principal face value of $937,500 to an accredited investor under Section 4(a)(2) exemption. The note is convertible into common stock at a price equal to the lesser of $0.05 or 80% of the average of the 5 lowest intraday trading prices in the prior 20 days, with a registration statement required for resale of conversion shares.","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CEROW","filing_date":"2026-05-29","form":"8-K","submitted_at":null,"items":[{"id":2755,"accession_number":"0001213900-26-062802","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company issued a convertible promissory note for $750,000 with a principal face value of $937,500 that is convertible into common stock at a price equal to the lesser of $0.05 or 80% of the average of the 5 lowest intraday trading prices in the prior 20 days. This is a dilutive equity issuance structured as a convertible debt instrument, which is a classic PIPE-like financing mechanism. The conversion price formula (80% of trailing average) and the requirement to file a registration statement for resale of conversion shares are hallmarks of dilutive private placements that materially affect shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:32:34.489859+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2756,"accession_number":"0001213900-26-062802","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, which typically discloses material acquisitions, dispositions, mergers, or changes of control. The creation of a direct financial obligation in this context signals M\u0026A activity rather than a standalone debt covenant or financing event. Without the full Item 1.01 text, the cross-reference structure strongly suggests a material transaction has been entered into.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:32:34.489859+00:00","company_name":"","ticker":null,"filing_date":""},{"id":2757,"accession_number":"0001213900-26-062802","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 3.02 discloses an unregistered sale of a convertible note under Section 4(a)(2) of the Securities Act to an accredited investor. The note is convertible into common stock, making this a dilutive issuance. The filing explicitly references Item 1.01 for details on the transaction, and the reliance on private placement exemptions is a hallmark of dilutive equity financing at smaller public companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:32:34.489859+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2755,"accession_number":"0001213900-26-062802","item_number":"1.01","item_title":"Entry into a Material Definitive","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The Company issued a convertible promissory note for $750,000 with a principal face value of $937,500 that is convertible into common stock at a price equal to the lesser of $0.05 or 80% of the average of the 5 lowest intraday trading prices in the prior 20 days. This is a dilutive equity issuance structured as a convertible debt instrument, which is a classic PIPE-like financing mechanism. The conversion price formula (80% of trailing average) and the requirement to file a registration statement for resale of conversion shares are hallmarks of dilutive private placements that materially affect shareholder equity and voting power.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:32:34.489859+00:00","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CEROW","filing_date":"2026-05-29"},{"id":2756,"accession_number":"0001213900-26-062802","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Item 2.03 incorporates Item 1.01 by reference, which typically discloses material acquisitions, dispositions, mergers, or changes of control. The creation of a direct financial obligation in this context signals M\u0026A activity rather than a standalone debt covenant or financing event. Without the full Item 1.01 text, the cross-reference structure strongly suggests a material transaction has been entered into.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:32:34.489859+00:00","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CEROW","filing_date":"2026-05-29"},{"id":2757,"accession_number":"0001213900-26-062802","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This Item 3.02 discloses an unregistered sale of a convertible note under Section 4(a)(2) of the Securities Act to an accredited investor. The note is convertible into common stock, making this a dilutive issuance. The filing explicitly references Item 1.01 for details on the transaction, and the reliance on private placement exemptions is a hallmark of dilutive equity financing at smaller public companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-30T02:32:34.489859+00:00","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","ticker":"CEROW","filing_date":"2026-05-29"}]}